BMRN Q2 2021 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$502M+16.8% YoY

Gross Profit

$375M74.7% margin

Operating Income

$12M2.3% margin

Net Income

$13M2.6% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+3.2%

Cash Flow

Operating Cash Flow

$83M

Free Cash Flow

$60M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$5.9B

Total Liabilities

$1.7B

Stockholders' Equity

$4.2B

Cash & Equivalents

$642M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$502M	$429M	+16.8%
Gross Profit	$375M	$332M	+13.0%
Operating Income	$12M	-$41M	+128.5%
Net Income	$13M	-$29M	+144.3%

Revenue Segments

Product

$487M97%

Royalty And Other

$15M3%

Geographic Segments

UNITED STATES

$204M41%

Europe

$173M34%

Rest Of World

$83M16%

Latin America

$42M8%